Firstly, one of the questions asked in the webinar was whether, if DCCR was approved next year, those taking it could still participate in any Phase 3 trial of NNZ-2591. The answer was that it was possible, provided it wasn’t within the exclusion criteria.
I’m fairly sure that it would be possible, if both therapies were approved, to take them concomitantly. They have different mechanisms of action. Perhaps results would be better than either drug used alone.
But I severely doubt that payers would agree to simultaneously reimburse both drugs for a patient if the potential combined cost was, say, US$800,000 per year.
- Forums
- ASX - By Stock
- NEU
- PHASE2 PRADER WILLI SYNDROME START !!!!
PHASE2 PRADER WILLI SYNDROME START !!!!, page-32
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B |
Open | High | Low | Value | Volume |
$20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 156 | $20.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.68 | 256 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 56 | 20.670 |
1 | 985 | 20.650 |
1 | 996 | 20.560 |
1 | 100 | 20.500 |
1 | 100 | 20.410 |
Price($) | Vol. | No. |
---|---|---|
20.740 | 50 | 1 |
21.400 | 1213 | 1 |
21.470 | 100 | 1 |
21.500 | 1072 | 3 |
21.850 | 9100 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |